Literature DB >> 17989941

Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes.

John A Hansen1, Effie W Petersdorf, Ming-Tseh Lin, Steven Wang, Jason W Chien, Barry Storer, Paul J Martin.   

Abstract

Successful outcome following hematopoietic stem cell transplantation (HSCT) is ultimately determined by the ability to achieve sustained engraftment and immune reconstitution, control of graft-versus-host disease (GVHD), and in patients with hematological malignancy the complete eradication of abnormal or malignant cells. GVHD, which can be a serious and fatal complication, is an immune reaction that is initiated by donor T cells in response to recipient alloantigens. Genetic variation in both patient and donor can significantly affect transplant outcome by causing disparity for transplant antigens, and by altering the function of immune response genes that control cellular activation and inflammation. Genetic variation can modulate the intensity of the alloimmune response, the risk of transplant-related organ toxicity and mortality, and may also affect the development of tolerance and the reconstitution of the immune system following HSCT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17989941     DOI: 10.1007/s12026-007-0043-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  112 in total

Review 1.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

2.  Bone-marrow transplantation from an HL-A non-identical but mixed-lymphocyte-culture identical donor.

Authors: 
Journal:  Lancet       Date:  1973-05-26       Impact factor: 79.321

Review 3.  The inheritance of leukocyte antigens.

Authors:  D B Amos
Journal:  Transplantation       Date:  1967-07       Impact factor: 4.939

Review 4.  Cellular immunology and the pathogenesis of graft versus host reactions.

Authors:  W L Elkins
Journal:  Prog Allergy       Date:  1971

5.  Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.

Authors:  D Przepiorka; T L Smith; J Folloder; I Khouri; N T Ueno; R Mehra; M Körbling; Y O Huh; S Giralt; J Gajewski; M Donato; K Cleary; D Claxton; I Braunschweig; K van Besien; B S Andersson; P Anderlini; R Champlin
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

6.  Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination.

Authors:  Ernst Holler; Gerhard Rogler; Julia Brenmoehl; Joachim Hahn; Hans Herfarth; Hildegard Greinix; Anne M Dickinson; Gerard Socié; Daniel Wolff; Gottfried Fischer; Graham Jackson; Vanderson Rocha; Beate Steiner; Guenther Eissner; Jeorg Marienhagen; Juergen Schoelmerich; Reinhard Andreesen
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

7.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

8.  Treatment of severe combined immunodeficiency with bone-marrow from an unrelated, mixed-leucocyte-culture-non-reactive donor.

Authors:  S D Horowitz; F H Bach; T Groshong; R Hong; E J Yunis
Journal:  Lancet       Date:  1975-09-06       Impact factor: 79.321

9.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

Authors:  Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

10.  Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation.

Authors:  D J Curtis; A Smale; F Thien; A P Schwarer; J Szer
Journal:  Bone Marrow Transplant       Date:  1995-07       Impact factor: 5.483

View more
  10 in total

1.  What Next? The Next Transit from Biology to Diagnostics: Next Generation Sequencing for Immunogenetics.

Authors:  Christian Gabriel; Stephanie Stabentheiner; Martin Danzer; Johannes Pröll
Journal:  Transfus Med Hemother       Date:  2011-09-25       Impact factor: 3.747

Review 2.  Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality.

Authors:  John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

3.  Correlation between microsatellite discrepancy scores and transplant outcome after haemopoietic SCT for pediatric ALL.

Authors:  J Harvey; A Green; S J Groves; J Cornish; J Moppett; M Cummins; L Keen; S Culliford; A Poles; W Hulme; Y Li; C G Steward
Journal:  Bone Marrow Transplant       Date:  2015-01-12       Impact factor: 5.483

4.  Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.

Authors:  Francesca Bonifazi; Gianluca Storci; Giuseppe Bandini; Elena Marasco; Elisa Dan; Elena Zani; Fiorenzo Albani; Sara Bertoni; Andrea Bontadini; Sabrina De Carolis; Maria Rosaria Sapienza; Simonetta Rizzi; Maria Rosa Motta; Martina Ferioli; Paolo Garagnani; Michele Cavo; Vilma Mantovani; Massimiliano Bonafè
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

Review 5.  NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges.

Authors:  Smita Bhatia; Stella M Davies; K Scott Baker; Michael A Pulsipher; John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-18       Impact factor: 5.742

6.  Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation.

Authors:  Yasuo Morishima; Takakazu Kawase; Mari Malkki; Satoko Morishima; Stephen Spellman; Koichi Kashiwase; Shunichi Kato; Anne Cesbron; Jean-Marie Tiercy; David Senitzer; Andrea Velardi; Effie W Petersdorf
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-06       Impact factor: 5.742

7.  The role of bacteria and pattern recognition receptors in GVHD.

Authors:  E Holler; K Landfried; J Meier; M Hausmann; G Rogler
Journal:  Int J Inflam       Date:  2010-10-31

Review 8.  Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.

Authors:  Marieke Griffioen; Cornelis A M van Bergen; J H Frederik Falkenburg
Journal:  Front Immunol       Date:  2016-03-15       Impact factor: 7.561

Review 9.  Toward personalized cell therapies by using stem cells: seven relevant topics for safety and success in stem cell therapy.

Authors:  Fernando de Sá Silva; Paula Nascimento Almeida; João Vitor Paes Rettore; Claudinéia Pereira Maranduba; Camila Maurmann de Souza; Gustavo Torres de Souza; Rafaella de Souza Salomão Zanette; Sueli Patricia Harumi Miyagi; Marcelo de Oliveira Santos; Márcia Martins Marques; Carlos Magno da Costa Maranduba
Journal:  J Biomed Biotechnol       Date:  2012-11-20

Review 10.  NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment.

Authors:  Antonio Pierini; Maite Alvarez; Robert S Negrin
Journal:  Stem Cells Int       Date:  2016-01-05       Impact factor: 5.443

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.